Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyperpolarized helium-3 is an inhaled, non-radioactive noble gas isotope used as a contrast agent for magnetic resonance imaging (MRI) of the lungs. The gas is hyperpolarized using spin-exchange optical pumping (SEOP) to significantly enhance its nuclear magnetic resonance signal, allowing for high-resolution, real-time visualization of lung ventilation, microstructure, and regional oxygen tension. It is primarily used in research settings to evaluate obstructive lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and emphysema, as well as to monitor lung transplant recipients for bronchiolitis obliterans syndrome (BOS). While generally well-tolerated, its inhalation can lead to transient oxyhemoglobin desaturation due to the displacement of oxygen in the lungs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyperpolarized helium-3.